Hot Topics

Association of BENLYSTA™ (belimumab) with hypersensitivity and infusion reactions

GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of important new safety information related to hypersensitivity and infusion reactions associated with BENLYSTA™ (belimumab) treatment. Read more

 

Are you registered for OPA's most exciting education event of the year?

Time is running out to take advantage of the special early bird rate – register for Conference 2012 today!
June 14-16
London Convention Centre

Conference 2012 is just a few weeks away, and the early bird registration deadline is approaching fast. Register by May 14 to save up to $50 on the conference registration fee. Find out more here.
 

CTV’s Lifetime: Pharmacist vaccinations

On March 30, CTV News aired an interview with Allan Malek, OPA's Senior Vice President, Professional Affairs, Drug Information and Continuing Education about pharmacists' expanding scope of practice, focusing on injection and immunization. Watch the interview here: http://toronto.ctv.ca/?video=648777
 

Sandoz Morphine Sulfate Injection USP 2mg/ml (1ml ampoules) – DIN 02242484

The Ontario Pharmacists' Association, working in collaboration with the Ontario Ministry of Health and Long-Term Care and Health Canada’s Health Products and Food Branch, is advising all pharmacists and their team members to be aware of a safety warning related to Sandoz Morphine Sulfate Injection USP. Some boxes of Sandoz Morphine Sulfate Injection USP 2mg/ml (1ml ampoules), DIN 02242484, may contain ampoules labeled as Isoproterenol Hydrochloride Injection 0.2mg/ml (1ml ampoules), DIN 00897639, in addition to ampoules labeled as containing morphine. Read more.
 

Ministry update on the drug shortage issue

To address the current drug shortages, the Ministry of Health and Long-Term Care has developed an action plan that includes health care system strategies for inventory and impact assessment, inventory management, facilitated procurement, modification of services and communications. Read more.
 

OPA wins CFP Innovation Fund grant for hypertension project

The Ontario Pharmacists’Association-Green Shield Canada Hypertension Collaborative.is the winner of this year’s Canadian Foundation for Pharmacy Innovation Fund grant in support of pharmacy practice research. Read more
 

Clinical documentation for pharmaceutical opinions

Phase 1 of the Pharmaceutical Opinion Program, implemented April 1, 2011, is best categorized as dispensing or transactional services that positively impact patient care and represent services pharmacists have been routinely providing to patients but without compensation. Most notable are the pharmaceutical opinion as well as services that verify adherence, tolerance and response to medication therapy. Read more
 

 
CE update


For a full list of OPA’s 2012 education programs,
click here.

 

Welcome to the Ontario Pharmacists' Association

The Ontario Pharmacists' Association (OPA) represents the views and interests of more than 13,600 pharmacists and pharmacists-in-training across the province. We work to inspire excellence in the profession and practice of pharmacy, and to promote wellness for patients.

Our members work in community pharmacies, family health teams, long-term care facilities, hospitals, universities, business and government, and practice in more than 3,000 clinical settings. Read more

Member Login

:

   
    Forgot your password?